Edgar Filing: NANOVIRICIDES, INC. - Form NT 10-K

NANOVIRICIDES, INC. Form NT 10-K September 28, 2012
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): x Form 10-K "Form 20-F" Form 11-K" Form 10-Q "Form N-SAR
For Period Ended: June 30, 2012
o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K
o Transition Report on Form 10-Q
o Transition Report on Form N-SAR
For the Transition Period Ended:
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates

P	ART	I-	REGISTI	RANT	INFOR	MATION
\mathbf{r}	111	1 -	VEQ1911	$\mathbf{N}\mathbf{A}\mathbf{N}\mathbf{I}$	INTUN	VIA LIUN

<u>Nano</u>	Vir	<u>ici</u>	<u>des,</u>	Inc.

Full Name of Registrant

135 Wood Street, Suite 205

Address of Principal Executive Office (Street and Number)

West Haven, Connecticut 06516

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
 - The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the
- S(b) prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PA	1	R	Т	T	M	_	N	J,	4	R	R	A	П	ויו	ī	7	\mathbf{F}

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof could not be filed within the prescribed period.

The Registrant ("we" or "us" or "our") will not be able to timely file our Annual Report on Form 10-K for the period ended June 30, 2012 without unreasonable effort or expense. We will file our Form 10-K when our independent auditor has completed its review of our financial statements. We believe this will be completed within the time prescribed for the filing.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contract in regard to this notification.

Eugene Seymour (203) 937-6137 (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

x Yes o No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Edgar Filing: NANOVIRICIDES, INC. - Form NT 10-K

o Yes x No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

NanoViricides, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 28, 2012

By: /s/ Eugene Seymour Eugene Seymour, Chief Executive and Financial Officer